PRKG1 and Myocardial fibrosis: A recent study has shown that sacubitril/valsartan can significantly improve stress-induced myocardial fibrosis by regulating atrial natriuretic peptide-induced PKG signaling in cardiac fibroblasts and inhibiting the expression of fibroblast transformation-related processes, which are not generated by treatment with the molar equivalent of valsartan (Burke et al., 2019), and our results are consistent with these changes.